Beaumont Financial Advisors LLC Purchases 129 Shares of Eli Lilly and Company (NYSE:LLY)

Beaumont Financial Advisors LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 2.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,356 shares of the company’s stock after buying an additional 129 shares during the quarter. Beaumont Financial Advisors LLC’s holdings in Eli Lilly and Company were worth $3,705,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Simon Quick Advisors LLC lifted its stake in shares of Eli Lilly and Company by 10.5% in the 4th quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock valued at $1,706,000 after purchasing an additional 278 shares during the period. Clear Harbor Asset Management LLC acquired a new position in Eli Lilly and Company in the fourth quarter valued at approximately $363,000. WASHINGTON TRUST Co lifted its stake in Eli Lilly and Company by 16.5% in the fourth quarter. WASHINGTON TRUST Co now owns 18,892 shares of the company’s stock valued at $11,013,000 after buying an additional 2,671 shares during the period. Liontrust Investment Partners LLP acquired a new position in Eli Lilly and Company in the third quarter valued at approximately $8,326,000. Finally, Redhawk Wealth Advisors Inc. lifted its stake in Eli Lilly and Company by 0.9% in the third quarter. Redhawk Wealth Advisors Inc. now owns 6,986 shares of the company’s stock valued at $3,752,000 after buying an additional 65 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY traded down $13.61 during mid-day trading on Friday, reaching $732.34. 1,933,410 shares of the company’s stock were exchanged, compared to its average volume of 3,051,768. The firm has a market capitalization of $695.84 billion, a price-to-earnings ratio of 125.67, a price-to-earnings-growth ratio of 1.64 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. Eli Lilly and Company has a 52 week low of $369.76 and a 52 week high of $800.78. The firm has a 50-day moving average price of $764.24 and a two-hundred day moving average price of $658.28.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. During the same quarter in the prior year, the business earned $2.09 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 28.1% on a year-over-year basis. Analysts predict that Eli Lilly and Company will post 12.52 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on LLY. Truist Financial reissued a “buy” rating and issued a $850.00 price target on shares of Eli Lilly and Company in a research note on Friday, March 22nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $815.00 price target on shares of Eli Lilly and Company in a research note on Monday. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Citigroup upped their target price on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. Finally, The Goldman Sachs Group upped their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $728.05.

Insider Transactions at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the sale, the insider now owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.